Compare IDEXX Laboratories, Inc. (IDXX) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs PayPal Holdings, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $571.44 (market cap $46.22B), while PayPal Holdings, Inc. trades at $58.47 (market cap $50.47B). The key difference: IDEXX Laboratories, Inc. and PayPal Holdings, Inc. are close in size by market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PYPL | |
|---|---|---|
Market Cap | $46.22B | $50.47B |
Sector | Health | Financials |
52-Week High | $766.68 | $76.13 |
52-Week Low | $526.44 | $39.08 |
Enterprise Value | $47.12B | $52.62B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
PayPal (PYPL) trades at $58.43, down 1.08% on the day, with a bullish technical signal from moving averages and a neutral RSI near 69. The stock shows strong fundamentals with a P/E of 11.15, net income margin of 14.36%, and revenue growth to $33.17B in 2025. Recent Q2 2026 earnings beat expectations with EPS of $1.38, and the company raised full-year guidance, signaling a turnaround under new leadership. News highlights include acquisition interest from Stripe and Advent International, rejected as too low, and expanded partnerships like Synchrony's Mastercard financing.
PYPL presents a value opportunity with low valuation multiples and robust cash flow, but faces risks from competitive pressures and economic sensitivity. Analyst consensus is mixed with a $58.75 price target, while institutional activity shows both position increases and cuts. The stock's upside depends on execution of the turnaround plan and sustained transaction volume growth amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
